GlassScriptPhysician profile
Michael Shelton
NPI 1003810995
$5,535.07
in general payments reported to CMS, 2019-2025
30 companies · $35.45 in 2025
The $35.45 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $694 · 2020: $983 · 2021: $1,204 · 2022: $1,092 · 2023: $1,012 · 2024: $516 · 2025: $35.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,563.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,562.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,050.84 | 2019-2024 | Breztri, Farxiga |
| Novo Nordisk INC | $656.86 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $604.23 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $543.47 | 2019-2024 | Repatha, Otezla, Prolia |
| Amarin Pharma, INC. | $297.49 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $295.06 | 2019-2022 | |
| Pfizer INC. | $249.15 | 2019-2025 | |
| Abbvie INC. | $248.72 | 2021-2024 | Vraylar, Ubrelvy |
| Sanofi-Aventis U.S. LLC | $214.66 | 2019-2023 | |
| Astellas Pharma US INC | $208.36 | 2021-2024 | Veozah, Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $147.33 | 2019-2024 | Trintellix |
| Glaxosmithkline, LLC. | $143.69 | 2021-2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $99.91 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $97.24 | 2022 | |
| Janssen Pharmaceuticals, INC | $89.36 | 2020-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $86.66 | 2020-2021 | |
| Abbott Laboratories | $75.22 | 2021-2023 | Freestyle Libre 3 |
| Zyla Life Sciences, INC. | $70.79 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $64.95 | 2020-2023 | Rexulti |
| Exact Sciences Corporation | $53.84 | 2023-2024 | Cologuard Collection Kit |
| Ironshore Pharmaceuticals INC. | $51.44 | 2019-2020 | |
| Allergan, INC. | $47.30 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $38.83 | 2021 | |
| Axsome Therapeutics, INC. | $17.93 | 2023 | Auvelity |
| Dexcom, INC. | $15.50 | 2024 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.83 | 2022 | |
| International Rehabilitative Sciences, INC | $13.66 | 2024 | Rs 4i Plus Sequential Stimulator |
| Avanir Pharmaceuticals, INC. | $12.89 | 2019 | |
| Tactile Systems Technology INC | $12.57 | 2022 | |
| Arbor Pharmaceuticals, INC. | $12.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Shelton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.